drugset
drugset / Trial / NCT07208981

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

NCT07208981 ↗

Phase 2 Recruiting 169 enrolled The First Affiliated Hospital with Nanjing Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase 2, non-randomized study aiming to evaluate the efficacy and safety of orelabrutinib combined with zebetuzumab and lenalidomide or bendamustine combined with rituximab in the treatment of newly diagnosed marginal zone lymphoma (MZL).

Timeline

Start
2025-08-14
Primary completion
2028-06-01
Completion
2031-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bendamustine Small molecule 90 mg/m2 —
Subject Lenalidomide Other / unclassified 20 mg —
Subject Orelabrutinib Small molecule 150 mg —
Comparator Rituximab Monoclonal antibody 375 mg/m2 —
Subject Zebetuzumab Unknown 375 mg/m2 —

Indications

marginal zone lymphoma